More than 86,000 recorded cases of respiratory syncytial virus in 2024 were in children younger than four years old.

The 30-day risks of hospitalization were 17.5%, 15.9%, and 14.4% for COVID, influenza, and RSV, respectively, during the 2022 ...

Shionogi’s oral antiviral for respiratory syncytial virus (RSV) has met its primary endpoint in a Phase II study that saw ...

While Sanofi’s immunology megablockbuster Dupixent predictably dominated the company’s sales charts in 2024, a new golden ...

Shionogi’s respiratory syncytial virus (RSV) antiviral for adults has proven its ability to reduce viral load in a phase 2 ...

Lower rates of both progression of macular fibrosis and intravitreal aflibercept injections were found in those who used the ...

The Cyprus pulmonology society on Thursday urged Health Minister Michael Damianos to approve a respiratory syncytial virus ...

U.S. surges of COVID-19, influenza, respiratory syncytial virus (RSV) and norovirus have collectively been dubbed a ...

The Health Protection Surveillance Centre (HPSC) has reported a further reduction in cases of flu, the Respiratory Syncytial ...

A new study is showing a policy change in 2016 related to the vaccination of some premature babies for RSV in Nova Scotia led ...

RSV is usually contagious for three to eight days. A patient also may be contagious a day or two before experiencing symptoms ...